Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Canertinib
CHF 60.00
In stock
SYN-1030-M0011 mgCHF 60.00
SYN-1030-M0055 mgCHF 78.00
SYN-1030-M01010 mgCHF 84.00
SYN-1030-M05050 mgCHF 311.00
SYN-1030-M100100 mgCHF 515.00
| Product Details | |
|---|---|
| Synonyms | CI1033; PD-183805 |
| Product Type | Chemical |
| Properties | |
| Formula | C24H25ClFN5O3 |
| MW | 486.0 |
| CAS | 267243-28-7 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO or ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: EGFR | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | OMZCMEYTWSXEPZ-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Canertinib is an orally bio-available EGFR inhibitor with potential anti-neoplastic and radio-sensitizing activities. It has IC(50) values of 1.5nM and 9.0nM against EGFR and ErbB2 respectively, with no activity against PDGFR, FGFR, InsR, PKC, or CDK1/2/4.
Product References
- The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux: C. Erlichman, et al.; Cancer Res. 61, 739 (2001)
Related Products
